HC Wainwright restated their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock.
Processa Pharmaceuticals Stock Down 1.5 %
Shares of NASDAQ PCSA opened at $1.31 on Thursday. The firm has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.79. The stock has a market capitalization of $3.74 million, a price-to-earnings ratio of -0.26 and a beta of 0.59. Processa Pharmaceuticals has a 52 week low of $1.24 and a 52 week high of $18.00.
Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.03). As a group, equities research analysts expect that Processa Pharmaceuticals will post -3.78 EPS for the current year.
About Processa Pharmaceuticals
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
Featured Stories
- Five stocks we like better than Processa Pharmaceuticals
- Manufacturing Stocks Investing
- Beat the Volatility: Top 3 Low-Beta Stocks to Watch
- Financial Services Stocks Investing
- Visa and Mastercard: Top Payment Stocks to Watch After Rate Cuts
- What Are Some of the Best Large-Cap Stocks to Buy?
- When Is the Best Time to Invest in Mutual Funds?
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
